Hepatitis B Trial, Recruiting NCT03920618 Sponsor: Third Affiliated Hospital, Sun Yat-Sen University Condition: Hepatitis B
Back to Hepatitis B

Hepatitis B Trial, Recruiting

NCT03920618
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have tested positive for hepatitis B surface antigen, or have had detectable hepatitis B virus in their blood, for more than 6 months
  • People aged between 12 and 65 years old
  • People whose blood test shows a bilirubin level (a measure of liver stress) more than 10 times the normal upper limit
  • People whose blood clotting tests show reduced clotting ability, specifically a prothrombin time activity below 40% or a prothrombin time international ratio above 1.5 (confirm with trial site if unsure what these mean)
  • People who have not taken antiviral medications known as nucleotide or nucleoside analogues in the past 6 months

Who may not be able to join:

  • People who have other active liver diseases in addition to hepatitis B
  • People who have liver cancer or any other type of cancer
  • People who are pregnant or currently breastfeeding
  • People who have HIV infection or a condition where the immune system does not work properly from birth
  • People who have severe diabetes or autoimmune diseases
  • People who have serious problems affecting other major organs in the body
  • People who are currently taking steroid medications known as glucocorticoids
  • People who would not be able to attend follow-up appointments as required by the trial
  • People whom the trial investigator considers unsuitable for the trial for any other reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Liang Peng, Doctor, Third Affiliated Hospital, Sun Yat-Sen University

Phone: +8613760783281

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Third Affiliated Hospital, Sun Yat-Sen University
Registry
ClinicalTrials.gov
Start date
21 February 2019
Est. completion
31 December 2024

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Survival rate in the follow-up

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov